EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF PF-04991532, A LIVER-TARGETED GLUCOKINASE ACTIVATOR AND OATP SUBSTRATE

被引：0
|
作者：
Bergman, A. [1 ]
Pfefferkorn, J. [2 ]
Litchfield, J. [1 ]
Wang, X. [1 ]
Kazierad, D. J. [2 ]
机构：
[1] Pfizer Inc, Groton, CT 06340 USA
[2] Pfizer Inc, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 13 条
  • [1] EFFECT OF THE OATP INHIBITOR CYCLOSPORINE ON THE ORAL PHARMACOKINETICS OF PF-04991532, AN OATP MEDIATED LIVER TARGETED SUBSTRATE
    Bergman, A.
    Pfefferkorn, J.
    Wang, C.
    Varma, M.
    Litchfield, J.
    Kazierad, D. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S35 - S35
  • [2] The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats
    Erion, Derek M.
    Lapworth, Amanda
    Amor, Paul A.
    Bai, Guoyun
    Vera, Nicholas B.
    Clark, Ronald W.
    Yan, Qingyun
    Zhu, Yimin
    Ross, Trenton T.
    Purkal, Julie
    Gorgoglione, Matthew
    Zhang, Guodong
    Bonato, Vinicius
    Baker, Levenia
    Barucci, Nicole
    D'Aquila, Theresa
    Robertson, Alan
    Aiello, Robert J.
    Yan, Jiangli
    Trimmer, Jeff
    Rolph, Timothy P.
    Pfefferkorn, Jeffrey A.
    PLOS ONE, 2014, 9 (05):
  • [3] Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-04991532, a Hepatoselective Glucokinase Activator (GKA), in T2DM Patients on Metformin Therapy
    Gustavson, Stephanie M.
    Pfefferkorn, Jeffrey A.
    Kazierad, David J.
    Chen, Danny
    Bergman, Arthur
    Wang, Xin
    Rolph, Timothy
    Rusnak, James M.
    DIABETES, 2013, 62 : A671 - A671
  • [4] The Hepatoselective Glucokinase (GK) Activator PF-04991532 Provides Additive Improvements in Glycemic Control With Exercise in Goto-Kakizaki Rats
    Ross, Trenton T.
    Beebe, David A.
    Erion, Derek M.
    Amor, Paul A.
    Zhu, Yimin
    Tesz, Gregory J.
    Yan, Qingyun
    Carvajal-Gonzalez, Santos
    Rolph, Timothy P.
    Pfefferkorn, Jeffrey A.
    Esler, William P.
    DIABETES, 2013, 62 : A291 - A291
  • [5] Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-04991532, a Hepatoselective Glucokinase Activator (GKA), Administered as Monotherapy in Japanese and Non-Japanese T2DM Patients
    Kazierad, David
    Bergman, Arthur
    Pfefferkorn, Jeffrey A.
    Wang, Xin
    Rolph, Timothy
    Rusnak, James M.
    DIABETES, 2013, 62 : A287 - A288
  • [6] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PK) MODELS FOR THE PREDICTION OF CYP DDIS FOR THE LIVER TARGETED GLUCOKINASE ACTIVATOR PF-04991532.
    Callegari, E.
    Varma, M.
    Litchfield, J.
    Bergman, A.
    Kazierad, D. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S35 - S35
  • [7] Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment
    Sharma, Raman
    Litchfield, John
    Bergman, Arthur
    Atkinson, Karen
    Kazierad, David
    Gustavson, Stephanie M.
    Di, Li
    Pfefferkorn, Jeffrey A.
    Kalgutkar, Amit S.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (02) : 190 - 198
  • [8] Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator
    Miao, Jia
    Fu, Ping
    Ren, Shuang
    Hu, Chao
    Wang, Ying
    Jiao, Chengfeng
    Li, Ping
    Zhao, Yu
    Tang, Cui
    Qian, Yuli
    Yang, Rong
    Dong, Yanli
    Rong, Jing
    Wang, Yaohui
    Jin, Xiaowei
    Sun, Yu
    Chen, Li
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (02): : 548 - 557
  • [9] The Hepatoselective Glucokinase Activator (GKA) PF-04991532, Lowers HbA1c after 12-Weeks of Dosing in Patients With Type 2 Diabetes (T2DM)
    Kazierad, David J.
    Pfefferkorn, Jeffrey A.
    Bergman, Arthur
    Wang, Xin
    Rolph, Timothy P.
    Rusnak, James M.
    DIABETES, 2013, 62 : A271 - A271
  • [10] Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation
    Bergman, Arthur
    Bi, Yi-an
    Mathialagan, Sumathy
    Litchfield, John
    Kazierad, David J.
    Pfefferkorn, Jeffrey A.
    Varma, Manthena V. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (04) : 792 - 802
12